Clinical Trials Directory

Trials / Unknown

UnknownNCT05735262

pBFS Guided Precision Neuromodulation Treatment for ASD

Personalized Brain Functional Sectors (pBFS) Guided Precision Neuromodulation Treatment for Autism Spectrum Disorder (ASD): a Single-center, Sham-controlled, Double-blinded, Randomized Clinical Trial Study

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Changping Laboratory · Academic / Other
Sex
All
Age
6 Years – 30 Years
Healthy volunteers
Not accepted

Summary

This study aims to evaluate the neuromodulation (i.e., iTBS) effectiveness for treating autism spectrum disorder (ASD) by targeting at the pBFS-guided executive function brain network or social brain network.

Detailed description

Autism spectrum disorder is characterized by executive function deficiency and social interaction difficulty. Using the developed technique, personalized brain functional sectors (pBFS), we could precisely identify individualized brain function networks based on the resting-state functional MRI scan. A tailored dorsal lateral prefrontal cortex (DLPFC) region situated within the executive function network and a tailored dorsal medial prefrontal cortex (DMPFC) region situated within the social network will be selected as intervention targets. The participants will be equally randomized to the following three groups, active iTBS to the left DLPFC, active iTBS to the left DMPFC, and sham iTBS to either the left DLPFC or left DMPFC at a ratio of 2:2:1:1. Each participant will receive 1800 pulse active or sham iTBS (100% RMT) in each session, 3 sessions daily, 5 days per week for 8 weeks, as well as background behavioral training between iTBS sessions.

Conditions

Interventions

TypeNameDescription
DEVICEactive iTBSEach participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
DEVICEsham iTBSEach participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.

Timeline

Start date
2023-03-07
Primary completion
2024-03-01
Completion
2025-01-01
First posted
2023-02-21
Last updated
2023-05-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05735262. Inclusion in this directory is not an endorsement.